首页 > 最新文献

Journal of Blood Medicine最新文献

英文 中文
Can COVID-19 Increase Platelet in Adult Immune Thrombocytopenia During the TPO-RA Administration? A Real-World Observational Study. 服用 TPO-RA 期间,COVID-19 能否增加成人免疫性血小板减少症患者的血小板?一项真实世界观察研究。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-05-07 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S457545
Xiaoyu Wang, Yingqiao Zhu, Dan Liu, Lijun Zhu, Juan Tong, Changcheng Zheng

Introduction: COVID-19 infection has brought new challenges to the treatment of adult patients with immune thrombocytopenia (ITP). In adult ITP patients, there have been no relevant reports exploring the incidence, clinical characteristics, and risk factors of platelet elevation after COVID-19 infection.

Materials and methods: A total of 66 patients with previously diagnosed ITP from December 2022 to February 2023 in a single-center were collected and analyzed for this real-world clinical retrospective observational study.

Results: In the platelet count increased group (n = 19), 13 patients (68.4%) were using thrombopoietin receptor agonists (TPO-RA) treatment at the time of COVID-19 infection; the median platelet count was 52 (2-207) ×109/L at the last visit before infection and 108 (19-453) ×109/L at the first visit after infection. In the platelet count stable group (n = 19) and platelet count decreased group (n = 28), 9 (47.4%) and 8 (28.6%) patients were using TPO-RA at the time of infection, respectively. ITP patients treated with TPO-RA had a significantly higher risk of increased platelet count than those not treated with TPO-RA at the time of infection (platelet count increased group vs platelet count decreased group: OR: 5.745, p = 0.009; platelet count increased group vs the non-increased group: OR: 3.616, p = 0.031). In the platelet count increased group, the median platelet count at 6 months post-infection was 67 (14-235) × 109/L, which was significantly higher than the platelet level at the last visit before infection (p = 0.040).

Conclusion: This study showed that some adult ITP patients had an increase in platelet count after COVID-19 infection, and this phenomenon was strongly associated with the use of TPO-RA at the time of infection. Although no thrombotic events were observed in this study, it reminds clinicians that they should be alert to the possibility of thrombotic events in the long-term management of adult ITP patients during the COVID-19 pandemic.

简介:COVID-19感染给成人免疫性血小板减少症(ITP)患者的治疗带来了新的挑战。在成人ITP患者中,尚未有相关报道探讨COVID-19感染后血小板升高的发生率、临床特征和风险因素:在这项真实世界临床回顾性观察研究中,收集并分析了一家单中心从2022年12月至2023年2月共66例既往诊断为ITP的患者:在血小板计数增加组(n=19)中,13例患者(68.4%)在感染COVID-19时正在使用促血小板生成素受体激动剂(TPO-RA)治疗;感染前最后一次就诊时的血小板计数中位数为52(2-207)×109/L,感染后首次就诊时的血小板计数中位数为108(19-453)×109/L。在血小板计数稳定组(n = 19)和血小板计数下降组(n = 28)中,分别有 9 名(47.4%)和 8 名(28.6%)患者在感染时正在使用 TPO-RA。感染时,接受 TPO-RA 治疗的 ITP 患者血小板计数增加的风险明显高于未接受 TPO-RA 治疗的患者(血小板计数增加组 vs 血小板计数减少组:OR:5.745,P = 0.009;血小板计数增加组与未增加组相比:OR:3.616, p = 0.031).在血小板计数增加组,感染后 6 个月的血小板计数中位数为 67 (14-235) × 109/L,显著高于感染前最后一次就诊时的血小板水平(P = 0.040):本研究表明,部分成年 ITP 患者在感染 COVID-19 后血小板计数增加,而这一现象与感染时使用 TPO-RA 密切相关。虽然本研究未观察到血栓事件,但它提醒临床医生在COVID-19大流行期间对成年ITP患者进行长期管理时应警惕血栓事件的可能性。
{"title":"Can COVID-19 Increase Platelet in Adult Immune Thrombocytopenia During the TPO-RA Administration? A Real-World Observational Study.","authors":"Xiaoyu Wang, Yingqiao Zhu, Dan Liu, Lijun Zhu, Juan Tong, Changcheng Zheng","doi":"10.2147/JBM.S457545","DOIUrl":"10.2147/JBM.S457545","url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19 infection has brought new challenges to the treatment of adult patients with immune thrombocytopenia (ITP). In adult ITP patients, there have been no relevant reports exploring the incidence, clinical characteristics, and risk factors of platelet elevation after COVID-19 infection.</p><p><strong>Materials and methods: </strong>A total of 66 patients with previously diagnosed ITP from December 2022 to February 2023 in a single-center were collected and analyzed for this real-world clinical retrospective observational study.</p><p><strong>Results: </strong>In the platelet count increased group (n = 19), 13 patients (68.4%) were using thrombopoietin receptor agonists (TPO-RA) treatment at the time of COVID-19 infection; the median platelet count was 52 (2-207) ×10<sup>9</sup>/L at the last visit before infection and 108 (19-453) ×10<sup>9</sup>/L at the first visit after infection. In the platelet count stable group (n = 19) and platelet count decreased group (n = 28), 9 (47.4%) and 8 (28.6%) patients were using TPO-RA at the time of infection, respectively. ITP patients treated with TPO-RA had a significantly higher risk of increased platelet count than those not treated with TPO-RA at the time of infection (platelet count increased group vs platelet count decreased group: OR: 5.745, p = 0.009; platelet count increased group vs the non-increased group: OR: 3.616, p = 0.031). In the platelet count increased group, the median platelet count at 6 months post-infection was 67 (14-235) × 10<sup>9</sup>/L, which was significantly higher than the platelet level at the last visit before infection (p = 0.040).</p><p><strong>Conclusion: </strong>This study showed that some adult ITP patients had an increase in platelet count after COVID-19 infection, and this phenomenon was strongly associated with the use of TPO-RA at the time of infection. Although no thrombotic events were observed in this study, it reminds clinicians that they should be alert to the possibility of thrombotic events in the long-term management of adult ITP patients during the COVID-19 pandemic.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"217-225"},"PeriodicalIF":2.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11088401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Consequences of Sickle Cell Disease. 镰状细胞病的心血管后果。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-05-06 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S455564
Salem Bahashwan, Rahaf Mohammad Almuhanna, Maryam Taher Al Hazza, Reem Wajdi Baarma, Abdulrahman Yousif AlNajjar, Faris Sameer Siddiqui, Shouq Ziyad Fatani, Ahmed Barefah, Hatem Alahwal, Abdullah Almohammadi, Osman Radhwi, Alaa S Algazzar, Eman M Mansory

Background: Sickle cell disease is an inherited blood disorder which can lead to severe complications, particularly in the cardiovascular and respiratory systems, potentially resulting in arrhythmias, pulmonary hypertension (PH), and cardiomegaly. This study aims to investigate the risk of PH and arrhythmias in adult SCD patients.

Methods: Retrospective analysis of medical records from King Abdulaziz University Hospital (KAUH) for patients with SCD aged 15 and above between 2009 and 2021. The study included 517 patients, with echocardiograms and electrocardiograms assessed according to the European Society of Cardiology/the European Respiratory Society (ESC/ERS) guidelines for categorizing PH risk (low, moderate, high) and detecting arrhythmias. Data analysis employed the Statistical Package for the Social Sciences (SPSS), utilizing quantitative and qualitative data representation. Multivariate logistic regression identified independent risk factors with odds ratios at a 95% confidence interval (CI).

Results: Among participants, 50.3% were male, with a total sample average age of 34.45 ± 9.28 years. Results indicated that 1.4% of patients experienced arrhythmias, 3.7% had a moderate PH risk, and 3.3% were classified as high PH risk. Logistic regression revealed significant independent risk factors for PH and arrhythmia in patients with SCD, with chronic kidney disease (CKD) carrying the highest odds (26.4 times higher odds of PH and 15.36 times higher odds of arrhythmias).

Conclusion: Patients with SCD are at risk for developing PH and various arrhythmias but are often underdiagnosed. Key risk factors for PH included CKD, liver cirrhosis, and pre-existing cardiac conditions. Arrhythmias were significantly associated with CKD and pre-existing cardiac conditions. To mitigate these risks, we recommend involving a multidisciplinary healthcare team in the care of adult patients with SCD. Future prospective studies are advised for early detection of PH and arrhythmias in hemoglobinopathy patients, potentially reducing mortality.

背景:镰状细胞病是一种遗传性血液疾病,可导致严重的并发症,尤其是心血管和呼吸系统的并发症,可能导致心律失常、肺动脉高压(PH)和心脏肥大。本研究旨在调查成年 SCD 患者 PH 和心律失常的风险:回顾性分析阿卜杜勒阿齐兹国王大学医院(KAUH)2009 年至 2021 年期间 15 岁及以上 SCD 患者的医疗记录。研究纳入了 517 名患者,并根据欧洲心脏病学会/欧洲呼吸学会(ESC/ERS)关于 PH 风险分类(低、中、高)和检测心律失常的指南对超声心动图和心电图进行了评估。数据分析采用社会科学统计软件包(SPSS),利用定量和定性数据表示。多变量逻辑回归确定了独立的风险因素,其几率比为 95% 的置信区间 (CI):参与者中,50.3%为男性,样本平均年龄为(34.45 ± 9.28)岁。结果显示,1.4%的患者有心律失常,3.7%的患者有中度PH风险,3.3%的患者被归类为高PH风险。逻辑回归显示,SCD 患者 PH 和心律失常的独立风险因素显著,其中慢性肾脏疾病(CKD)的几率最高(PH 几率是 CKD 的 26.4 倍,心律失常几率是 CKD 的 15.36 倍):结论:SCD 患者有患 PH 和各种心律失常的风险,但往往诊断不足。PH的主要风险因素包括慢性肾脏病、肝硬化和原有心脏病。心律失常与慢性肾功能衰竭和原有心脏疾病密切相关。为了降低这些风险,我们建议让多学科医疗团队参与 SCD 成年患者的护理。建议今后开展前瞻性研究,以便及早发现血红蛋白病患者的 PH 和心律失常,从而降低死亡率。
{"title":"Cardiovascular Consequences of Sickle Cell Disease.","authors":"Salem Bahashwan, Rahaf Mohammad Almuhanna, Maryam Taher Al Hazza, Reem Wajdi Baarma, Abdulrahman Yousif AlNajjar, Faris Sameer Siddiqui, Shouq Ziyad Fatani, Ahmed Barefah, Hatem Alahwal, Abdullah Almohammadi, Osman Radhwi, Alaa S Algazzar, Eman M Mansory","doi":"10.2147/JBM.S455564","DOIUrl":"10.2147/JBM.S455564","url":null,"abstract":"<p><strong>Background: </strong>Sickle cell disease is an inherited blood disorder which can lead to severe complications, particularly in the cardiovascular and respiratory systems, potentially resulting in arrhythmias, pulmonary hypertension (PH), and cardiomegaly. This study aims to investigate the risk of PH and arrhythmias in adult SCD patients.</p><p><strong>Methods: </strong>Retrospective analysis of medical records from King Abdulaziz University Hospital (KAUH) for patients with SCD aged 15 and above between 2009 and 2021. The study included 517 patients, with echocardiograms and electrocardiograms assessed according to the European Society of Cardiology/the European Respiratory Society (ESC/ERS) guidelines for categorizing PH risk (low, moderate, high) and detecting arrhythmias. Data analysis employed the Statistical Package for the Social Sciences (SPSS), utilizing quantitative and qualitative data representation. Multivariate logistic regression identified independent risk factors with odds ratios at a 95% confidence interval (CI).</p><p><strong>Results: </strong>Among participants, 50.3% were male, with a total sample average age of 34.45 ± 9.28 years. Results indicated that 1.4% of patients experienced arrhythmias, 3.7% had a moderate PH risk, and 3.3% were classified as high PH risk. Logistic regression revealed significant independent risk factors for PH and arrhythmia in patients with SCD, with chronic kidney disease (CKD) carrying the highest odds (26.4 times higher odds of PH and 15.36 times higher odds of arrhythmias).</p><p><strong>Conclusion: </strong>Patients with SCD are at risk for developing PH and various arrhythmias but are often underdiagnosed. Key risk factors for PH included CKD, liver cirrhosis, and pre-existing cardiac conditions. Arrhythmias were significantly associated with CKD and pre-existing cardiac conditions. To mitigate these risks, we recommend involving a multidisciplinary healthcare team in the care of adult patients with SCD. Future prospective studies are advised for early detection of PH and arrhythmias in hemoglobinopathy patients, potentially reducing mortality.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"207-216"},"PeriodicalIF":2.0,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11086457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140911260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Montana Interfacility Blood Network: A Novel Lifesaving "Hand-off" for the Optimal Care of Rural Patients. 蒙大拿州医院间血液网络:新颖的救生 "交接",为农村患者提供最佳护理。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-03-20 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S442134
Gordon M Riha, Alyssa Johnson, Sadie Arnold, Michael S Englehart, Simon J Thompson

Purpose: The state of Montana encompasses and defines rural health care as it is known in the United States (US) today. This vast area is punctuated by pockets of health care availability with varying access to blood products for transfusion. Furthermore, timely transport is frequently challenged by weather that may limit air transportation options, resulting in multiple hours in ground transport to definitive care.

Patients and methods: The Montana State Trauma Care Committee (MT-STCC) developed the Montana Interfacility Blood Network (MT-IBN) to ensure blood availability in geographically distanced cases where patients may otherwise not survive. The index case that led to the formal development of the MT-IBN is described, followed by a second case illustrating the IBN process.

Results: This process and development manuscript details the innovative efforts of MT-STCC to develop this fledgling idea unique to rural US health care. We review guidelines that have been developed to define broad aspects of the MT-IBN including the reason to share resources, proper packaging, paperwork necessary for transfer, and how to provide resources directly to the patient. Finally, we describe implementation within the state.

Conclusion: The MT-IBN was developed by MT-STCC to facilitate the hand-off of lifesaving blood to patients being transported by ground to definitive care in Montana without having to stop at an intermediary facility. This has already led to lives saved in areas that are limited in blood availability due to rurality.

目的:蒙大拿州涵盖并定义了当今美国的农村医疗保健。在这片广袤的土地上,各地的医疗服务设施不尽相同,但获得输血用血液制品的途径却各不相同。此外,及时转运经常受到天气的影响,因为天气可能会限制空中运输的选择,导致地面运输需要多个小时才能到达最终医疗机构:蒙大拿州创伤救护委员会(Montana State Trauma Care Committee,MT-STCC)建立了蒙大拿设施间血液网络(Montana Interfacility Blood Network,MT-IBN),以确保在地理位置偏远的病例中血液的供应,否则患者可能无法存活。本文介绍了促使蒙大拿州医疗机构间血液网络正式发展的病例,并通过第二个病例说明了医疗机构间血液网络的发展过程:本过程与开发手稿详细介绍了 MT-STCC 为开发这一美国农村医疗保健领域独有的新兴理念所做的创新努力。我们回顾了为确定 MT-IBN 的广泛方面而制定的指导方针,包括共享资源的原因、适当包装、转移所需的文书工作以及如何直接向患者提供资源。最后,我们介绍了该州的实施情况:MT-IBN 是由 MT-STCC 研发的,旨在为蒙大拿州通过陆路转运到最终医疗机构的患者提供救生血液,而无需在中间设施停留。这已经在一些因偏远而血液供应有限的地区挽救了生命。
{"title":"The Montana Interfacility Blood Network: A Novel Lifesaving \"Hand-off\" for the Optimal Care of Rural Patients.","authors":"Gordon M Riha, Alyssa Johnson, Sadie Arnold, Michael S Englehart, Simon J Thompson","doi":"10.2147/JBM.S442134","DOIUrl":"10.2147/JBM.S442134","url":null,"abstract":"<p><strong>Purpose: </strong>The state of Montana encompasses and defines rural health care as it is known in the United States (US) today. This vast area is punctuated by pockets of health care availability with varying access to blood products for transfusion. Furthermore, timely transport is frequently challenged by weather that may limit air transportation options, resulting in multiple hours in ground transport to definitive care.</p><p><strong>Patients and methods: </strong>The Montana State Trauma Care Committee (MT-STCC) developed the Montana Interfacility Blood Network (MT-IBN) to ensure blood availability in geographically distanced cases where patients may otherwise not survive. The index case that led to the formal development of the MT-IBN is described, followed by a second case illustrating the IBN process.</p><p><strong>Results: </strong>This process and development manuscript details the innovative efforts of MT-STCC to develop this fledgling idea unique to rural US health care. We review guidelines that have been developed to define broad aspects of the MT-IBN including the reason to share resources, proper packaging, paperwork necessary for transfer, and how to provide resources directly to the patient. Finally, we describe implementation within the state.</p><p><strong>Conclusion: </strong>The MT-IBN was developed by MT-STCC to facilitate the hand-off of lifesaving blood to patients being transported by ground to definitive care in Montana without having to stop at an intermediary facility. This has already led to lives saved in areas that are limited in blood availability due to rurality.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"141-146"},"PeriodicalIF":2.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10961070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140206896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and Associated Factors of Anemia among Newborns at Jimma Medical Center, South-west Ethiopia. 埃塞俄比亚西南部吉马医疗中心新生儿贫血症患病率及相关因素。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-03-13 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S443312
Gebeyaw Arega Berihun, Girum Tesfaye, Wondimagegn Adissu, Edosa Tadasa, Kidist Adamu, Abinet Tantu Kombe, Lealem Gedefaw

Background: Newborn anemia is among the most common hematological problems and it can cause asymptomatic or severe to acute life-threatening events. It leads to impairment in brain maturation and development, tissue hypoxia, and stunted growth and then arrested growth if left untreated. The prevalence of anemia among newborns ranges from 23.4-66% in sub-Saharan Africa. But, there is limited information in Ethiopia regarding the prevalence of newborn anemia and its risk factors. Therefore, this study aimed to determine the prevalence of newborn anemia and its associated factors at Jimma Medical Center (JMC), South-west Ethiopia.

Methods: A hospital-based cross-sectional study design was implemented from January 14 to February 28, 2021, involving 288 full-term newborns by employing consecutive convenient sampling technique for study participant selection. Socio-demographic data and other associated factors were collected through interviews and a review of medical records by a structured questionnaire. Three mL umbilical cord blood samples from each newborn were collected and analyzed for a complete blood count by an automated hematological analyzer. Data were entered into Epi Data version 3.1 and exported to Statistical Package for Social Science version 20 for analysis. Binary logistic regression were used to identify the predictors of newborn anemia.

Results: The overall prevalence of anemia among newborns was 26.4%; of them, 65.8%, 25%, and 9.2% were mild, moderate, and severe anemia types, respectively. Maternal vegetable consumption habit (AOR = 0.26, 95% CI: 0.11, 0.62) and maternal anemia (AOR = 0.34, 95% CI: 0.17, 0.69) were significantly associated with anemia in newborns.

Conclusion: In general, newborn anemia in this study was a moderate public health problem. Based on this study, early screening of anemia among newborns may reduce further complications. Prevention of maternal anemia during pregnancy by improving their nutritional status especially vegetable consumption had a positive impact on reducing anemia among newborns.

背景:新生儿贫血是最常见的血液病之一,可导致无症状或严重到危及生命的急性贫血。如果不及时治疗,会导致大脑成熟和发育障碍、组织缺氧、生长发育迟缓和生长停滞。在撒哈拉以南非洲地区,新生儿贫血症的发病率为 23.4-66%。但在埃塞俄比亚,有关新生儿贫血患病率及其风险因素的信息非常有限。因此,本研究旨在确定埃塞俄比亚西南部吉马医疗中心(Jimma Medical Center,JMC)的新生儿贫血患病率及其相关因素:方法:于 2021 年 1 月 14 日至 2 月 28 日实施了一项基于医院的横断面研究设计,采用连续方便抽样技术选取了 288 名足月新生儿作为研究对象。通过访谈和查阅病历,以结构化问卷的形式收集社会人口学数据和其他相关因素。研究人员收集了每名新生儿的三毫升脐带血样本,并用自动血液分析仪对样本进行了全血细胞计数分析。数据输入 Epi Data 3.1 版,并导出到社会科学统计软件包 20 版进行分析。二元逻辑回归用于确定新生儿贫血的预测因素:结果:新生儿贫血总患病率为 26.4%,其中轻度、中度和重度贫血分别占 65.8%、25% 和 9.2%。产妇蔬菜消费习惯(AOR = 0.26,95% CI:0.11,0.62)和产妇贫血(AOR = 0.34,95% CI:0.17,0.69)与新生儿贫血显著相关:总体而言,本研究中的新生儿贫血是一个中等程度的公共卫生问题。根据这项研究,对新生儿进行早期贫血筛查可减少进一步的并发症。通过改善孕产妇的营养状况,尤其是蔬菜摄入量来预防孕期贫血,对减少新生儿贫血有积极影响。
{"title":"Prevalence and Associated Factors of Anemia among Newborns at Jimma Medical Center, South-west Ethiopia.","authors":"Gebeyaw Arega Berihun, Girum Tesfaye, Wondimagegn Adissu, Edosa Tadasa, Kidist Adamu, Abinet Tantu Kombe, Lealem Gedefaw","doi":"10.2147/JBM.S443312","DOIUrl":"10.2147/JBM.S443312","url":null,"abstract":"<p><strong>Background: </strong>Newborn anemia is among the most common hematological problems and it can cause asymptomatic or severe to acute life-threatening events. It leads to impairment in brain maturation and development, tissue hypoxia, and stunted growth and then arrested growth if left untreated. The prevalence of anemia among newborns ranges from 23.4-66% in sub-Saharan Africa. But, there is limited information in Ethiopia regarding the prevalence of newborn anemia and its risk factors. Therefore, this study aimed to determine the prevalence of newborn anemia and its associated factors at Jimma Medical Center (JMC), South-west Ethiopia.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study design was implemented from January 14 to February 28, 2021, involving 288 full-term newborns by employing consecutive convenient sampling technique for study participant selection. Socio-demographic data and other associated factors were collected through interviews and a review of medical records by a structured questionnaire. Three mL umbilical cord blood samples from each newborn were collected and analyzed for a complete blood count by an automated hematological analyzer. Data were entered into Epi Data version 3.1 and exported to Statistical Package for Social Science version 20 for analysis. Binary logistic regression were used to identify the predictors of newborn anemia.</p><p><strong>Results: </strong>The overall prevalence of anemia among newborns was 26.4%; of them, 65.8%, 25%, and 9.2% were mild, moderate, and severe anemia types, respectively. Maternal vegetable consumption habit (AOR = 0.26, 95% CI: 0.11, 0.62) and maternal anemia (AOR = 0.34, 95% CI: 0.17, 0.69) were significantly associated with anemia in newborns.</p><p><strong>Conclusion: </strong>In general, newborn anemia in this study was a moderate public health problem. Based on this study, early screening of anemia among newborns may reduce further complications. Prevention of maternal anemia during pregnancy by improving their nutritional status especially vegetable consumption had a positive impact on reducing anemia among newborns.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"129-140"},"PeriodicalIF":2.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10950678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Study: Rosai-Dorfman Disease and Its Multifaceted Aspects. 病例研究:罗赛-多夫曼病及其多面性。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-03-11 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S436720
Daniela Oliveira Werneck Rodrigues, Roberta Wolp Diniz, Leonardo Cunha Dentz, Monica de Albuquerque Costa, Roberto Heleno Lopes, Lucas Fernandes Suassuna, Jane Rocha Duarte Cintra, Christian Domenge

Rosai-Dorfman Disease (RDD) is a rare non-Langerhans histiocytosis, usually self-limited and presenting with massive, painless, bilateral cervical lymphadenopathy, with or without constitutional symptoms. Extranodal disease is frequently present, and may happen in the absence of lymph node involvement, symptomatology and differential diagnosis will depend on the site affected and fatal cases may occur. The authors present two cases of Rosai-Dorfman disease (RDD), diagnosed through immunohistochemistry, with different progressions, one with complete remission and one culminating in death, highlighting the variety of presentations and the diagnostic difficulty. RDD is a rare condition with clinical presentations similar to several diseases, and should be considered in the differential diagnosis of lymphadenopathy with extranodal lesions.

罗赛-多夫曼病(RDD)是一种罕见的非朗格汉斯组织细胞增生症,通常为自限性疾病,表现为巨大、无痛、双侧颈淋巴结肿大,伴或不伴全身症状。经常出现结节外疾病,也可能在没有淋巴结受累的情况下发生,症状和鉴别诊断取决于受累部位,也可能出现致命病例。作者介绍了两例通过免疫组化确诊的罗赛-多夫曼病(RDD)病例,病情发展各不相同,其中一例完全缓解,另一例最终死亡,突显了该病表现的多样性和诊断的困难性。RDD是一种罕见病,临床表现与多种疾病相似,在鉴别诊断淋巴腺病伴有结节外病变时应加以考虑。
{"title":"Case Study: Rosai-Dorfman Disease and Its Multifaceted Aspects.","authors":"Daniela Oliveira Werneck Rodrigues, Roberta Wolp Diniz, Leonardo Cunha Dentz, Monica de Albuquerque Costa, Roberto Heleno Lopes, Lucas Fernandes Suassuna, Jane Rocha Duarte Cintra, Christian Domenge","doi":"10.2147/JBM.S436720","DOIUrl":"10.2147/JBM.S436720","url":null,"abstract":"<p><p>Rosai-Dorfman Disease (RDD) is a rare non-Langerhans histiocytosis, usually self-limited and presenting with massive, painless, bilateral cervical lymphadenopathy, with or without constitutional symptoms. Extranodal disease is frequently present, and may happen in the absence of lymph node involvement, symptomatology and differential diagnosis will depend on the site affected and fatal cases may occur. The authors present two cases of Rosai-Dorfman disease (RDD), diagnosed through immunohistochemistry, with different progressions, one with complete remission and one culminating in death, highlighting the variety of presentations and the diagnostic difficulty. RDD is a rare condition with clinical presentations similar to several diseases, and should be considered in the differential diagnosis of lymphadenopathy with extranodal lesions.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"123-128"},"PeriodicalIF":2.0,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B. 一项授权后安全监测研究,报告纯化因子 IX 浓缩液在小儿血友病 B 患者中的临床经验。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-03-05 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S425617
Zoran Igrutinović, Hélène Louise Hooimeijer, Karim Kentouche, Jaco Botha, Peter L Turecek, Marta Kokot-Kierepa, Hanna T Gazda

Introduction: Purified factor IX (FIX) concentrate (IMMUNINE®, Takeda Manufacturing Austria AG, Vienna, Austria) is indicated for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia B. Data on the use of purified FIX concentrate in patients ≤6 years old with congenital hemophilia B are limited.

Aim: Document real-world clinical experience with purified FIX concentrate in routine practice for pediatric patients with hemophilia B.

Methods: This prospective post-authorization safety surveillance study enrolled patients ≤6 years old with moderate or severe hemophilia B (baseline FIX ≤5%) who were prescribed purified FIX concentrate, as determined by the treating physician. The planned observation period for each patient was either 12 months or ≥50 exposure days, whichever occurred first. The primary endpoints were the occurrence of treatment-related adverse events (AEs) and serious AEs (SAEs), and inhibitor development.

Results: Thirteen male patients (mean ± standard deviation age, 3.80 ± 1.76 years) enrolled and received ≥1 treatment with purified FIX concentrate. Thirty-two AEs were reported in 6 patients; 4 were SAEs. No AEs were considered related to purified FIX concentrate. No patients developed inhibitory antibodies. Inhibitor testing was not conducted in 2 patients. Eighteen bleeding episodes were treated with purified FIX concentrate in 6 patients. Hemostatic efficacy was rated as either "excellent" or "good" in all patients with an available rating.

Conclusion: No treatment-related AEs were reported, and purified FIX concentrate was shown to be effective in treating and preventing bleeding episodes in pediatric patients ≤6 years old with hemophilia B.

导言:纯化的IX因子(FIX)浓缩液(IMMUNINE®,Takeda Manufacturing Austria AG,奥地利维也纳)适用于先天性血友病B患者出血发作的治疗和预防。纯化的FIX浓缩液在6岁以下先天性血友病B患者中的使用数据有限:这项前瞻性授权后安全性监测研究招募了年龄≤6 岁的中度或重度 B 型血友病患者(基线 FIX ≤5%),这些患者由主治医生决定处方纯化 FIX 浓缩液。每位患者的计划观察期为 12 个月或接触天数≥50 天,以先发生者为准。主要终点是治疗相关不良事件(AE)和严重不良事件(SAE)的发生率以及抑制剂的发展情况:13名男性患者(平均年龄(标准差)为3.80±1.76岁)接受了≥1次纯化FIX浓缩液治疗。6名患者报告了32例AE,其中4例为SAE。未发现与纯化 FIX 浓缩液有关的不良反应。没有患者产生抑制性抗体。2 例患者未进行抑制剂检测。6 名患者使用纯化 FIX 浓缩液治疗了 18 次出血。所有患者的止血效果均被评为 "优 "或 "良":结论:未报告治疗相关的不良反应,纯化的 FIX 浓缩液可有效治疗和预防 6 岁以下 B 型血友病儿童患者的出血发作。
{"title":"A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B.","authors":"Zoran Igrutinović, Hélène Louise Hooimeijer, Karim Kentouche, Jaco Botha, Peter L Turecek, Marta Kokot-Kierepa, Hanna T Gazda","doi":"10.2147/JBM.S425617","DOIUrl":"10.2147/JBM.S425617","url":null,"abstract":"<p><strong>Introduction: </strong>Purified factor IX (FIX) concentrate (IMMUNINE<sup>®</sup>, Takeda Manufacturing Austria AG, Vienna, Austria) is indicated for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia B. Data on the use of purified FIX concentrate in patients ≤6 years old with congenital hemophilia B are limited.</p><p><strong>Aim: </strong>Document real-world clinical experience with purified FIX concentrate in routine practice for pediatric patients with hemophilia B.</p><p><strong>Methods: </strong>This prospective post-authorization safety surveillance study enrolled patients ≤6 years old with moderate or severe hemophilia B (baseline FIX ≤5%) who were prescribed purified FIX concentrate, as determined by the treating physician. The planned observation period for each patient was either 12 months or ≥50 exposure days, whichever occurred first. The primary endpoints were the occurrence of treatment-related adverse events (AEs) and serious AEs (SAEs), and inhibitor development.</p><p><strong>Results: </strong>Thirteen male patients (mean ± standard deviation age, 3.80 ± 1.76 years) enrolled and received ≥1 treatment with purified FIX concentrate. Thirty-two AEs were reported in 6 patients; 4 were SAEs. No AEs were considered related to purified FIX concentrate. No patients developed inhibitory antibodies. Inhibitor testing was not conducted in 2 patients. Eighteen bleeding episodes were treated with purified FIX concentrate in 6 patients. Hemostatic efficacy was rated as either \"excellent\" or \"good\" in all patients with an available rating.</p><p><strong>Conclusion: </strong>No treatment-related AEs were reported, and purified FIX concentrate was shown to be effective in treating and preventing bleeding episodes in pediatric patients ≤6 years old with hemophilia B.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"113-122"},"PeriodicalIF":2.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10933513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Presentation and Outcome of Patients with Multiple Myeloma (MM), Single Centre Experience from Windsor Essex Regional Cancer Centre. 温莎埃塞克斯地区癌症中心(Windsor Essex Regional Cancer Centre)的单中心经验:多发性骨髓瘤(MM)患者的表现和预后。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-02-26 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S434055
Dalia Kashash, Eric McArthur, Caroline Hamm, Rasna Gupta, Sindu Kanjeekal, Mohammad Jarrar, Lisa A Porter, John W Hudson, Adam Renaud, Indryas Woldie

Introduction: Outcomes for patients with multiple myeloma has significantly improved through the years. This is mainly related to the use of novel agents.

Methods: This is a retrospective study that reviewed presentation and outcome of 139 patients with multiple myeloma at the Windsor Essex Regional Cancer Centre from Jan. 1, 2015 to Dec. 31, 2019. Median age was 71 years and most patients had higher risk disease (65.5% either R ISS stage II or III). 30% had high risk FISH for myeloma including del.17P, t (4:14), t (14:16) and Gain (1q21). In terms of presentation, 38.8% had anemia (hemoglobin <100g/L), 18.7% had hypercalcemia, 74.1% had skeletal lytic lesions, 38.8% had pathologic fracture and 17.3% had plasmacytoma.

Results: Almost all (92%) of the patients were treated using at least one novel agent (proteasome inhibitor or immunomodulators [ImiDs]). Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) was the most used treatment regimen (48.9%) followed by bortezomib, melphalan and prednisone (BMP) at 28.8% and lenalidomide, dexamethasone (LenDex) at 14.4%. With respect to response to therapy, 51.8% had at least Very good partial response (VGPR), while 9.4% had progressive disease. 33% had autologous stem cell transplant. After a median follow up of 2.4 years, median overall survival was 3.7 years. 2 years overall survival and relapse-free survival were 70% and 83%, respectively.

Discussion: Our study showed comparable outcome for patients with multiple myeloma despite older age and higher risk disease. Outcome is expected to improve with the introduction of more novel agents.

前言多年来,多发性骨髓瘤患者的治疗效果有了明显改善。这主要与新型药物的使用有关:这是一项回顾性研究,回顾了温莎埃塞克斯地区癌症中心自2015年1月1日至2019年12月31日期间139名多发性骨髓瘤患者的发病情况和治疗结果。中位年龄为71岁,大多数患者患有高风险疾病(65.5%为R ISS II期或III期)。30%的患者患有骨髓瘤高风险FISH,包括del.17P、t(4:14)、t(14:16)和Gain(1q21)。就表现而言,38.8%的患者有贫血(血红蛋白结果):几乎所有患者(92%)都接受了至少一种新型药物(蛋白酶体抑制剂或免疫调节剂[ImiDs])的治疗。环磷酰胺、硼替佐米和地塞米松(CyBorD)是最常用的治疗方案(48.9%),其次是硼替佐米、美法兰和泼尼松(BMP)(28.8%)和来那度胺、地塞米松(LenDex)(14.4%)。在治疗反应方面,51.8%的患者至少有非常好的部分反应(VGPR),9.4%的患者病情进展。33%的患者进行了自体干细胞移植。中位随访期为2.4年,中位总生存期为3.7年。2年总生存率和无复发生存率分别为70%和83%:我们的研究表明,尽管多发性骨髓瘤患者年龄较大、患病风险较高,但他们的治疗效果相当。随着更多新型药物的引入,预后有望得到改善。
{"title":"Presentation and Outcome of Patients with Multiple Myeloma (MM), Single Centre Experience from Windsor Essex Regional Cancer Centre.","authors":"Dalia Kashash, Eric McArthur, Caroline Hamm, Rasna Gupta, Sindu Kanjeekal, Mohammad Jarrar, Lisa A Porter, John W Hudson, Adam Renaud, Indryas Woldie","doi":"10.2147/JBM.S434055","DOIUrl":"10.2147/JBM.S434055","url":null,"abstract":"<p><strong>Introduction: </strong>Outcomes for patients with multiple myeloma has significantly improved through the years. This is mainly related to the use of novel agents.</p><p><strong>Methods: </strong>This is a retrospective study that reviewed presentation and outcome of 139 patients with multiple myeloma at the Windsor Essex Regional Cancer Centre from Jan. 1, 2015 to Dec. 31, 2019. Median age was 71 years and most patients had higher risk disease (65.5% either R ISS stage II or III). 30% had high risk FISH for myeloma including del.17P, t (4:14), t (14:16) and Gain (1q21). In terms of presentation, 38.8% had anemia (hemoglobin <100g/L), 18.7% had hypercalcemia, 74.1% had skeletal lytic lesions, 38.8% had pathologic fracture and 17.3% had plasmacytoma.</p><p><strong>Results: </strong>Almost all (92%) of the patients were treated using at least one novel agent (proteasome inhibitor or immunomodulators [ImiDs]). Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) was the most used treatment regimen (48.9%) followed by bortezomib, melphalan and prednisone (BMP) at 28.8% and lenalidomide, dexamethasone (LenDex) at 14.4%. With respect to response to therapy, 51.8% had at least Very good partial response (VGPR), while 9.4% had progressive disease. 33% had autologous stem cell transplant. After a median follow up of 2.4 years, median overall survival was 3.7 years. 2 years overall survival and relapse-free survival were 70% and 83%, respectively.</p><p><strong>Discussion: </strong>Our study showed comparable outcome for patients with multiple myeloma despite older age and higher risk disease. Outcome is expected to improve with the introduction of more novel agents.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"101-111"},"PeriodicalIF":2.0,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnitude, Associated Factors and Morphological Types of Anemia Among Hospitalized 6-59 Months Age Children at Jimma Medical Center, Southwest Ethiopia - A Hospital-Based Cross-Sectional Study. 埃塞俄比亚西南部吉马医疗中心 6-59 个月大住院儿童贫血的严重程度、相关因素和形态类型--一项基于医院的横断面研究。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-02-26 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S442240
Regassa Alemu Kebede, Tilahun Yemane, Gebeyaw Arega Berihun, Tolera Ambisa Lamesa, Dereje Abebe Regasa

Background: Anemia is among the major public health problems that cause significant morbidity and mortality among children around the world. Anemia in children of age 6 months to 5 years is a major health problem in most developing world countries with estimated prevalence of about 43%.

Objective: To determine the magnitude, associated factors and morphological types of anemia among hospitalized 6-59 months age children from June 15 to October 15, 2022 at Jimma Medical Center, southwest Ethiopia.

Methodology: Hospital-based cross- sectional study design was conducted from June 15 to October 15, 2022 at Jimma Medical Center, involving 383 hospitalized children aged 6-59 months by employing convenient sampling technique. Data of sociodemographic characteristics and other associated factors of the study individuals waere collected using a pre-structured questionnaire. Clinical data were collected by physical examination and from history of client by medical interns and nurses. Then 3 mL venous blood was collected and analyzed for complete blood count. Data were coded, cleared and entered into EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable binary logistic regression was used to identify associated factors.

Results: The overall prevalence of anemia among hospitalized 6-59 months age children was 57.2%; out of them 30.82% were moderate. In the present study children with malaria infection, AOR = 1.15 (95% CI: 0.017, 0.781), Cchildren with severe malnutrition, AOR = 2.046 (95% CI: 0.306, 1.366), and children with low family income, AOR = 2.6 (95% CI 0.475, 0.894) were independent variables associated with anemia.

Conclusion and recommendation: Anemia among study participants is found to be a severe public health problem. Based on this finding, more intervention is needed with health education on nutrition and child feeding.

背景:贫血是导致全球儿童严重发病和死亡的主要公共卫生问题之一。6 个月至 5 岁儿童贫血是大多数发展中国家的主要健康问题,估计发病率约为 43%:方法:2022 年 6 月 15 日至 10 月 15 日,在埃塞俄比亚西南部的吉马医疗中心开展了基于医院的横断面研究,采用方便抽样技术,涉及 383 名 6-59 个月大的住院儿童。研究人员的社会人口学特征和其他相关因素的数据是通过预先设计的问卷收集的。临床数据由实习医生和护士通过体格检查和病史收集。然后采集 3 毫升静脉血,分析全血细胞计数。数据经编码、清除后输入 EpiData 4.6 版,并导出至 SPSS 25 版进行分析。采用二变量和多变量二元逻辑回归来确定相关因素:在住院的 6-59 个月大儿童中,贫血的总患病率为 57.2%,其中 30.82% 为中度贫血。在本研究中,感染疟疾的儿童(AOR = 1.15 (95% CI: 0.017, 0.781))、严重营养不良的儿童(AOR = 2.046 (95% CI: 0.306, 1.366))和家庭收入低的儿童(AOR = 2.6 (95% CI 0.475, 0.894))是与贫血相关的独立变量:研究发现,参与者中的贫血是一个严重的公共卫生问题。基于这一发现,需要对营养和儿童喂养方面的健康教育进行更多干预。
{"title":"Magnitude, Associated Factors and Morphological Types of Anemia Among Hospitalized 6-59 Months Age Children at Jimma Medical Center, Southwest Ethiopia - A Hospital-Based Cross-Sectional Study.","authors":"Regassa Alemu Kebede, Tilahun Yemane, Gebeyaw Arega Berihun, Tolera Ambisa Lamesa, Dereje Abebe Regasa","doi":"10.2147/JBM.S442240","DOIUrl":"10.2147/JBM.S442240","url":null,"abstract":"<p><strong>Background: </strong>Anemia is among the major public health problems that cause significant morbidity and mortality among children around the world. Anemia in children of age 6 months to 5 years is a major health problem in most developing world countries with estimated prevalence of about 43%.</p><p><strong>Objective: </strong>To determine the magnitude, associated factors and morphological types of anemia among hospitalized 6-59 months age children from June 15 to October 15, 2022 at Jimma Medical Center, southwest Ethiopia.</p><p><strong>Methodology: </strong>Hospital-based cross- sectional study design was conducted from June 15 to October 15, 2022 at Jimma Medical Center, involving 383 hospitalized children aged 6-59 months by employing convenient sampling technique. Data of sociodemographic characteristics and other associated factors of the study individuals waere collected using a pre-structured questionnaire. Clinical data were collected by physical examination and from history of client by medical interns and nurses. Then 3 mL venous blood was collected and analyzed for complete blood count. Data were coded, cleared and entered into EpiData version 4.6 and exported to SPSS version 25 for analysis. Bivariable and multivariable binary logistic regression was used to identify associated factors.</p><p><strong>Results: </strong>The overall prevalence of anemia among hospitalized 6-59 months age children was 57.2%; out of them 30.82% were moderate. In the present study children with malaria infection, AOR = 1.15 (95% CI: 0.017, 0.781), Cchildren with severe malnutrition, AOR = 2.046 (95% CI: 0.306, 1.366), and children with low family income, AOR = 2.6 (95% CI 0.475, 0.894) were independent variables associated with anemia.</p><p><strong>Conclusion and recommendation: </strong>Anemia among study participants is found to be a severe public health problem. Based on this finding, more intervention is needed with health education on nutrition and child feeding.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"87-99"},"PeriodicalIF":2.0,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10906273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in a Low-Middle Income Country: A Single-Center Experience in West Java, Indonesia. 中低收入国家儿童急性淋巴细胞白血病的存活率和治疗效果:印度尼西亚西爪哇的单中心经验。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-02-19 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S438042
Monika Hasna Ramadhan, Nur Melani Sari, Stanza Uga Peryoga, Susi Susanah

Purpose: This study aimed to determine the survival rates and treatment outcomes of patients with childhood Acute Lymphoblastic Leukemia (ALL) in a single-center study at Indonesia.

Patients and methods: Factors contributing to the relapse and survival of ALL in Bandung, Indonesia, were evaluated. Data were collected from the medical record and the Indonesian Pediatric Cancer Registry (IPCAR). Subsequently, univariate and multivariate analyses were evaluated using Cox proportional hazard regression and Kaplan Meier was used for survival analysis. An analytic observational study was conducted on newly diagnosed children aged 1-18 with ALL from January 2019 to December 2022.

Results: A total of 137 children were included in the analysis, 30 (21,9%) were dropped out during treatment and 60.5% died during the study period. Most of the deaths occurred after relapse in 32 (38.5%) with a high early relapse (70.5%), occurring mainly during the maintenance phase (42.4%). At the one-year mark, the observed overall survival (OS) rate was at 36%, while event-free survival (EFS) was lower, at 19%. Univariate Cox regression analysis showed that the leucocyte counts at diagnosis (p=0.005) and response to induction phase (p < 0.008) was associated with the death of ALL. Furthermore, a response to induction phase was significant [hazard ratio 4.67 (CI 95%: 1.64-13.29); p = 0.004] in the multivariate analysis.

Conclusion: In conclusion, this study underscored the persistent challenges of high treatment discontinuation rates and the occurrence of very early relapses in low- to middle-income countries (LMICs), which significantly impacted the OS of children diagnosed with ALL.

目的:本研究旨在通过印度尼西亚的一项单中心研究确定儿童急性淋巴细胞白血病(ALL)患者的存活率和治疗效果:研究评估了印度尼西亚万隆地区急性淋巴细胞白血病复发和存活的因素。数据收集自医疗记录和印尼儿科癌症登记处(IPCAR)。随后,使用Cox比例危险回归进行了单变量和多变量分析,并使用Kaplan Meier进行了生存分析。分析观察研究的对象是2019年1月至2022年12月新确诊的1-18岁ALL患儿:共有137名儿童纳入分析,30名(21.9%)在治疗期间退出,60.5%在研究期间死亡。大部分死亡发生在复发后,32 名儿童(38.5%)死亡,其中早期复发率较高(70.5%),主要发生在维持治疗阶段(42.4%)。一年后,观察到的总生存率(OS)为 36%,而无事件生存率(EFS)较低,为 19%。单变量考克斯回归分析显示,诊断时的白细胞计数(P=0.005)和对诱导阶段的反应(P < 0.008)与 ALL 的死亡有关。此外,在多变量分析中,对诱导阶段的反应具有显著性[危险比为4.67(CI 95%:1.64-13.29);P=0.004]:总之,本研究强调了中低收入国家(LMICs)持续存在的高治疗中断率和极早期复发的挑战,这严重影响了确诊为ALL的儿童的OS。
{"title":"Survival and Treatment Outcomes of Childhood Acute Lymphoblastic Leukemia in a Low-Middle Income Country: A Single-Center Experience in West Java, Indonesia.","authors":"Monika Hasna Ramadhan, Nur Melani Sari, Stanza Uga Peryoga, Susi Susanah","doi":"10.2147/JBM.S438042","DOIUrl":"https://doi.org/10.2147/JBM.S438042","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to determine the survival rates and treatment outcomes of patients with childhood Acute Lymphoblastic Leukemia (ALL) in a single-center study at Indonesia.</p><p><strong>Patients and methods: </strong>Factors contributing to the relapse and survival of ALL in Bandung, Indonesia, were evaluated. Data were collected from the medical record and the Indonesian Pediatric Cancer Registry (IPCAR). Subsequently, univariate and multivariate analyses were evaluated using Cox proportional hazard regression and Kaplan Meier was used for survival analysis. An analytic observational study was conducted on newly diagnosed children aged 1-18 with ALL from January 2019 to December 2022.</p><p><strong>Results: </strong>A total of 137 children were included in the analysis, 30 (21,9%) were dropped out during treatment and 60.5% died during the study period. Most of the deaths occurred after relapse in 32 (38.5%) with a high early relapse (70.5%), occurring mainly during the maintenance phase (42.4%). At the one-year mark, the observed overall survival (OS) rate was at 36%, while event-free survival (EFS) was lower, at 19%. Univariate Cox regression analysis showed that the leucocyte counts at diagnosis (p=0.005) and response to induction phase (p < 0.008) was associated with the death of ALL. Furthermore, a response to induction phase was significant [hazard ratio 4.67 (CI 95%: 1.64-13.29); p = 0.004] in the multivariate analysis.</p><p><strong>Conclusion: </strong>In conclusion, this study underscored the persistent challenges of high treatment discontinuation rates and the occurrence of very early relapses in low- to middle-income countries (LMICs), which significantly impacted the OS of children diagnosed with ALL.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"77-85"},"PeriodicalIF":2.0,"publicationDate":"2024-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10887884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing Nutritional Anemia Among University Students in Jazan, Saudi Arabia: A Public Health Perspective. 评估沙特阿拉伯贾赞大学生的营养性贫血:公共卫生视角。
IF 2 Q3 HEMATOLOGY Pub Date : 2024-02-09 eCollection Date: 2024-01-01 DOI: 10.2147/JBM.S436673
Waleed Hakami, Gasim Dobie, Khadija A Alneami, Misk Shaabi, Khaled Essawi, Muhammad Saboor, Aymen M Madkhali, Mohammed H Nahari, Hassan H Almasoudi, Mohammad S Akhter, Fasial H Hakami, Fatimah A Zarbatan, Ali Hakamy, Rama M Chandika, Ali A Fageehi, Abdullah A Mobarki, Hassan A Hamali

Background: Nutritional anemia is a significant public health concern worldwide, particularly affecting young adults and children in Saudi Arabia, where inadequate nutrition is considered a primary contributing factor. This study aims to (i) examine the levels of serum iron, folate, and vitamin B12 in young adult students, with a focus on identifying any deficiencies and their association with anemia; (ii) explore the prevalence of mixed-deficiency anemia resulting from deficiencies in serum iron, folate, and vitamin B12 (iii) explore how sociodemographic characteristics and dietary habits influence serum iron, folate, and vitamin B12 levels.

Materials and methods: This cross-sectional study encompassed 158 young adult students at Jazan University, Saudi Arabia. Blood samples were collected following a comprehensive questionnaire addressing sociodemographic and health characteristics. These samples were analyzed for complete blood count, serum iron, folate, and vitamin B12 levels.

Results: The findings of this study revealed a significant decrease in serum iron levels, with 70.6% of males and 88% in females exhibiting reduced level. Additionally, low levels of folate were observed in 4% of the study population, while deficiency in vitamin B12 was found in 2.2% of the study population. However, the simultaneous presence of low serum iron levels along with deficiencies in folate or vitamin B12 was not observed in the study participants.

Conclusion: The study indicates that there is a high incidence of low serum iron and ferritin levels among university students in Saudi Arabia, which poses a considerable public health concern. Conversely, the prevalence of folate and vitamin B12 deficiencies among the students was comparatively low, and notably, there were no cases where these deficiencies were observed alongside iron deficiency.

背景:营养性贫血是全球关注的重大公共卫生问题,尤其影响沙特阿拉伯的青壮年和儿童,而营养不足被认为是造成营养性贫血的主要因素。本研究的目的是:(i) 检查青壮年学生的血清铁、叶酸和维生素 B12 水平,重点是确定任何缺乏症及其与贫血的关系;(ii) 探讨因血清铁、叶酸和维生素 B12 缺乏而导致的混合型缺血性贫血的发病率;(iii) 探讨社会人口特征和饮食习惯如何影响血清铁、叶酸和维生素 B12 水平:这项横断面研究涵盖了沙特阿拉伯贾赞大学的 158 名青年学生。研究人员在进行了针对社会人口学和健康特征的综合问卷调查后采集了血液样本。对这些样本进行了全血细胞计数、血清铁、叶酸和维生素 B12 水平的分析:研究结果表明,血清铁含量显著下降,70.6% 的男性和 88% 的女性血清铁含量下降。此外,4% 的研究人群中发现叶酸水平偏低,2.2% 的研究人群中发现维生素 B12 缺乏。然而,在研究参与者中并未发现同时存在血清铁含量低和叶酸或维生素 B12 缺乏的情况:研究表明,沙特阿拉伯大学生中血清铁和铁蛋白水平低的发生率很高,这对公共健康构成了严重威胁。与此相反,学生中叶酸和维生素 B12 缺乏症的发病率相对较低,值得注意的是,没有发现这些缺乏症与铁缺乏症同时存在的病例。
{"title":"Assessing Nutritional Anemia Among University Students in Jazan, Saudi Arabia: A Public Health Perspective.","authors":"Waleed Hakami, Gasim Dobie, Khadija A Alneami, Misk Shaabi, Khaled Essawi, Muhammad Saboor, Aymen M Madkhali, Mohammed H Nahari, Hassan H Almasoudi, Mohammad S Akhter, Fasial H Hakami, Fatimah A Zarbatan, Ali Hakamy, Rama M Chandika, Ali A Fageehi, Abdullah A Mobarki, Hassan A Hamali","doi":"10.2147/JBM.S436673","DOIUrl":"10.2147/JBM.S436673","url":null,"abstract":"<p><strong>Background: </strong>Nutritional anemia is a significant public health concern worldwide, particularly affecting young adults and children in Saudi Arabia, where inadequate nutrition is considered a primary contributing factor. This study aims to (i) examine the levels of serum iron, folate, and vitamin B<sub>12</sub> in young adult students, with a focus on identifying any deficiencies and their association with anemia; (ii) explore the prevalence of mixed-deficiency anemia resulting from deficiencies in serum iron, folate, and vitamin B<sub>12</sub> (iii) explore how sociodemographic characteristics and dietary habits influence serum iron, folate, and vitamin B<sub>12</sub> levels.</p><p><strong>Materials and methods: </strong>This cross-sectional study encompassed 158 young adult students at Jazan University, Saudi Arabia. Blood samples were collected following a comprehensive questionnaire addressing sociodemographic and health characteristics. These samples were analyzed for complete blood count, serum iron, folate, and vitamin B<sub>12</sub> levels.</p><p><strong>Results: </strong>The findings of this study revealed a significant decrease in serum iron levels, with 70.6% of males and 88% in females exhibiting reduced level. Additionally, low levels of folate were observed in 4% of the study population, while deficiency in vitamin B<sub>12</sub> was found in 2.2% of the study population. However, the simultaneous presence of low serum iron levels along with deficiencies in folate or vitamin B<sub>12</sub> was not observed in the study participants.</p><p><strong>Conclusion: </strong>The study indicates that there is a high incidence of low serum iron and ferritin levels among university students in Saudi Arabia, which poses a considerable public health concern. Conversely, the prevalence of folate and vitamin B<sub>12</sub> deficiencies among the students was comparatively low, and notably, there were no cases where these deficiencies were observed alongside iron deficiency.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"51-60"},"PeriodicalIF":2.0,"publicationDate":"2024-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863464/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139729687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Blood Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1